ABT

Premium Grower

Abbott Laboratories · Healthcare · United States · $179.4B cap · $964.8M/day traded

$104.48 -0.2% · close 18 Nov · scored 19 Nov

Premium Grower: Strong business with the market behind it, priced at a premium.

63
Score
Get score and insider alerts

After its 21 Oct results, analysts cut next year's EPS estimate 2.0%.

Quality
63
Value
39
Momentum
57

As of 19 Nov 2026, the MoatMap Score for Abbott Laboratories (ABT) is 63/100, ranked against 25,000+ stocks in 38 markets (Quality 63, Value 39, Momentum 57, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
40.5x
peers 23.2x
ROE
9.1%
peers 3.1%
D/E
0.6x
peers 0.2x
Dividend %
2.3%
trailing yield

ABOUT ABBOTT LABORATORIES

Read

Abbott Laboratories is a diversified global healthcare company engaged in the discovery, development, manufacturing, and sale of a broad array of medical products across four segments: Diagnostics, Medical Devices, Nutritionals, and Established Pharmaceuticals. The company's formidable competitive moat stems from its diverse product portfolio addressing critical health needs, robust R&D pipeline, strong global brand recognition for products like FreeStyle Libre, and extensive regulatory and manufacturing expertise. This broad reach and innovation secure its leadership across multiple essential healthcare markets.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue43.1B43.7B40.1B42.0B44.3B0.7%48.2B49.9B53.5B9.9%
Net margin16.4%15.9%14.3%31.9%14.7%-1.7 pts————
EPS4.04.03.37.73.8-1.4%2.74.04.37.4%
Share count1.8B1.7B1.7B1.7B1.7B-0.5%1.7B———
Balance sheet
Debt—17.7B15.6B15.0B13.9B-7.9%31.4B———
Equity35.8B36.7B38.6B47.7B52.1B9.8%————
Debt/equity—0.5x0.4x0.3x0.3x-0.2x————
Cash flow
Op. cash flow10.5B9.6B7.3B8.6B9.6B-2.4%8.9B———
Cash flow margin24.5%21.9%18.1%20.4%21.6%-2.9 pts18.4%———
Investing CF-2.0B-1.7B-3.1B-2.3B-2.4B—————
Financing CF-5.5B-7.6B-7.1B-5.4B-6.3B—————
PRICE (1Y) · USD+6.1%
98.51031071111168 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 26 weeks, 29% above that low, but not back above a rising 50-day average.

The Momentum score still reads 57: it looks back six months, so it has not caught up with this fall.

SwingsCalm

Calmer than 76% of stocks we rank over the past year (volatility 29% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor (this stock): It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$104.48
RSI (14)
49.8
52-Week Range-18.9% from high
Low $80.89High $128.83

SCORE BREAKDOWN

Quality
63
ROIC
12.8%76.1
ROE
9.1%66.5
GP/Assets
31.8%67.6
Op. Margin
15.6%76.8
FCF/Assets
8.5%82.3
Piotroski
549.5
Int. Cover
18.2x70.2
D/E Ratio
0.61x24.4
Current Ratio
1.46x24.3
Value
39
P/E (TTM)
40.5x26.6
EV/EBITDA
18.8x34.4
P/FCF
24.3x46.6
P/B
3.7x34.0
P/S
3.9x45.4
Div Yield
2.3%60.7
Momentum
57
52W High %
81%73.8
RS 6M
21%78.0
SMA 50/200
1.03x69.0
EPS Rev 4W
-2.1%15.8
EPS Rev 12W
-2.1%25.3
EPS Improve
+122%80.1
Q Growth
-44%13.5

FUNDAMENTALS

Market Cap
$179.4B
P/E (Forward)
18.3x
Gross Margin
57.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABT are excluded.

TickerCompanyMkt CapScore
ABTAbbott Laboratories(you)$179.4B63
SYKStryker Corporation$117.8B58
MDTMedtronic plc$122.0B86
EWEdwards Lifesciences Corporation$51.3B77
BSXBoston Scientific Corporation$66.2B41
SHL.DESiemens Healthineers AG$52.5B87
300760.SZShenzhen Mindray Bio-Medical Electronics Co., Ltd.$32.2B77
SNNSmith & Nephew plc$12.9B64
GEHCGE HealthCare Technologies Inc.$32.3B83
PENPenumbra, Inc.$12.8B61

Peer medians: ROE 3.1% · P/E 23.2x · Gross margin 53.1%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Abbott Laboratories (ABT): Stock Score Summary

Abbott Laboratories (ABT) has a MoatMap Score of 63/100 based on Quality (63/100), Value (39/100), and Momentum (57/100) factor scores.

Abbott Laboratories is a diversified global healthcare company engaged in the discovery, development, manufacturing, and sale of a broad array of medical products across four segments: Diagnostics, Medical Devices, Nutritionals, and Established Pharmaceuticals. The company's formidable competitive moat stems from its diverse product portfolio addressing critical health needs, robust R&D pipeline, strong global brand recognition for products like FreeStyle Libre, and extensive regulatory and manufacturing expertise. This broad reach and innovation secure its leadership across multiple essential healthcare markets.

Director dealings

From 2 Jan 2026 to 19 Nov 2026, MoatMap's records hold 10 sales and 5 purchases of Abbott Laboratories (ABT) shares by its directors. The largest: Ford Robert B sold 398,832 shares at $115.85 on 25 Aug 2026 (about $46.2M).

  • 5 Nov 2026: Moreland Mary K sold 3,500 shares at $116.00 (about $406K)
  • 2 Sep 2026: MCCOY JOHN A. JR. sold 27 shares at $109.54 (about $3K)
  • 25 Aug 2026: Ford Robert B sold 398,832 shares at $115.85 (about $46.2M)
  • 11 Aug 2026: Morrone Louis H. sold 5,850 shares at $109.83 (about $643K)
  • 7 May 2026: Stratton John G bought 2,000 shares at $86.82 (about $174K)
ABT insider filings, last 180 days

Key Financial Metrics

Price$104.48
Market Cap$179.4B
P/E (TTM)40.49
P/E (Forward)18.28
Price/Book3.68
Return on Equity9.1%
Return on Invested Capital12.8%
Debt/Equity0.61x
Gross Margin57.2%
Operating Margin15.6%
Revenue Growth14.5%
Dividend Yield2.3%
Free Cash Flow$7.4B

Abbott Laboratories operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Abbott Laboratories’s (ABT) MoatMap Score?
The MoatMap Score for Abbott Laboratories (ABT) is 63/100. It is a composite of Quality (63), Value (39), and Momentum (57), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Abbott Laboratories have an economic moat?
Abbott Laboratories (ABT) has a Quality factor score of 63/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Abbott Laboratories in?
Abbott Laboratories (ABT) operates in the Healthcare sector, specifically the Medical Devices industry (United States).